This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Paclitaxel poliglumex
DrugBank Accession Number
DB13809
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Synonyms
  • Paclitaxel poliglumex
External IDs
  • CT-2103

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel poliglumex.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel poliglumex.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel poliglumex.
BevacizumabThe risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.
BleomycinThe risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel poliglumex.
BortezomibThe risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel poliglumex.
BusulfanThe risk or severity of cardiotoxicity can be increased when Busulfan is combined with Paclitaxel poliglumex.
CabazitaxelThe risk or severity of cardiotoxicity can be increased when Cabazitaxel is combined with Paclitaxel poliglumex.
CapecitabineThe risk or severity of cardiotoxicity can be increased when Capecitabine is combined with Paclitaxel poliglumex.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
L01CD03 — Paclitaxel poliglumex
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
TQ64FZ98ZN
CAS number
263351-82-2
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
RxNav
2473230

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer AJCC v7 / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3TerminatedTreatmentLung Cancers4
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentBreast Cancer / Metastatic Breast Cancer1
2CompletedTreatmentEsophageal Cancer1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentNeoplasms, Ovarian1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at June 23, 2017 20:49 / Updated at February 21, 2021 18:54